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Abstract The monomeric GTPase Rac and the lipid kinase
phosphoinositide 3-kinase (PI3K) are intracellular signalling en-
zymes that each regulate a huge range of cellular functions.
Their signalling pathways overlap. Several pathways lead from
PI3K activation via the production of the lipid second messenger
phosphatidylinositol (3,4,5)-triphosphate (PtdIns(3,4,5)P3) to
the activation of guanine-nucleotide exchange factors (GEFs)
that activate Rac. Vice versa, Rac can also stimulate the acti-
vation of PI3K, although the mechanism for this is unclear. We
review here the evidence that links PI3K and Rac signalling
pathways.
- 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Rac proteins (Rac1, 2 and 3) are a subfamily of the Rho
family of monomeric GTPases. They regulate a wide range of
universally important cellular functions including the struc-
ture of the actin cytoskeleton, cell/cell contacts and adhesion,
transcriptional and translational activation, protein synthesis,
cell survival and cell cycle entry [1,2]. In addition, Rac pro-
teins also control cell type-speci¢c functions such as regulated
secretion in mast cells, reactive oxygen species formation by
the NADPH oxidase complex in neutrophils, and axon guid-
ance in neurones [1].
All Rho family GTPases, including Rac proteins, are mo-
lecular switches that are inactive when guanosine diphosphate
(GDP)-bound and active when guanosine triphosphate
(GTP)-bound [3]. When GTP-bound, they bind to their target
proteins; for Rac, about 15 direct targets are currently known
[1]. In resting cells, Rac-GDP is inactive, cytosolic, and gen-
erally bound to a GDP dissociation inhibitor (GDI). After
dissociation of the GDI (the regulation of this step is still
unclear), Rac-GDP attaches to the membrane via its C-termi-
nal prenylation. This allows binding of the activating enzyme,
a guanine-nucleotide exchange factor (GEF). The GEF prises
open the GTPase’s nucleotide-binding site, allowing dissocia-
tion of GDP and binding of GTP (which is present at much
higher concentration than GDP in the cytosol of the cell).
Inactivation occurs by hydrolysis of bound GTP to GDP
through the intrinsic GTPase activity of Rac and can be ac-
celerated by a GTPase-activating protein. Although Rac acti-
vation can theoretically occur at several steps, i.e. removal of
the GDI, recruitment or activation of the GEF and removal
or inhibition of the guanosine triphosphatase-activating pro-
tein (GAP), the available evidence suggests that it depends
largely on the activation of the GEF [3] (Fig. 1).
Phosphoinositide 3-kinase (PI3K) family enzymes phos-
phorylate the phosphoinositide class of lipids at the 3-OH
position of the inositol ring [4]. Among them, type 1 PI3Ks
are regulated by stimulation of cell surface receptors. Type 1A
PI3Ks (PI3KK, L and N) are activated by receptor-tyrosine
kinases and intracellular protein-tyrosine kinases, whereas
type 1B PI3K (PI3KQ) is activated by G protein-coupled re-
ceptors via the LQ subunits of heterotrimeric G proteins.
Both type 1A and type 1B PI3Ks are also activated by Ras.
Upon activation, all type 1 PI3Ks phosphorylate phosphati-
dylinositol (4,5)-diphosphate (PtdIns(4,5)P2), a constitutive
membrane component, to create the lipid second messenger
phosphatidylinositol (3,4,5)-triphosphate (PtdIns(3,4,5)P3)
(and its immediate metabolic product PtdIns(3,4)P2). The
PtdIns(3,4,5)P3 signal is mediated by its binding to the plex-
trin homology (PH) domain of target proteins, which induces
their membrane translocation and/or conformational changes.
Known PtdIns(3,4,5)P3 targets are numerous and from a va-
riety of enzyme classes, e.g. protein kinases, phospholipases
and GEFs [4]. These PtdIns(3,4,5)P3 targets together regulate
a huge list of essential cellular functions including transcrip-
tion, translation, protein synthesis, cell survival, cell cycle en-
try and the structure of the actin cytoskeleton [4].
2. PI3K upstream of Rac
The wide overlap in cellular functions regulated by Rac
and type 1 PI3Ks has long suggested a link between their
signalling pathways. Indeed, there is now a large body of
evidence showing that PI3K can activate Rac indirectly via
PtdIns(3,4,5)P3-sensitive Rac-GEFs, as will be described be-
low. PtdIns(3,4,5)P3 can also bind directly to Rac in vitro,
and at high concentration (EC50 around 50 WM)
PtdIns(3,4,5)P3 can facilitate the dissociation of GDP from
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Rac [5]. However, PtdIns(3,4,5)P3 preferably binds and stabil-
ises the nucleotide-free form of Rac and does not promote
GTP loading [5]. Thus, the signi¢cance of this interaction
for the regulation of Rac in vivo is still unclear.
First indications that type 1A PI3K can be upstream of Rac
activation came from experiments using the PI3K inhibitor
wortmannin and dominant-negative PI3K constructs. They
were shown to inhibit the Rac-dependent pathways of plate-
let-derived growth factor (PDGF) and insulin-stimulated
membrane ru¥ing, and overexpression of wild type or con-
stitutively active Rac could override this inhibition [6^8]. For-
mal proof that type 1A PI3K is a necessary signal for Rac
activation in some situations came from direct measurements
of PDGF-stimulated, wortmannin-sensitive Rac-GTP loading
in a Rac-overexpressing endothelial cell line [7]. Later, co-ex-
pression of various combinations of GLQs, type 1B PI3K, and
the Rac-GEF Vav in COS cells has revealed that type 1B
PI3K is also capable of activating Rac, and implicated an
unidenti¢ed Rac-GEF as the mediator [9].
Since these studies, extensive use of PI3K inhibitors and
dominant-negative PI3K mutants has shown that PI3K is
necessary for Rac activation in a large number of di¡erent
systems. Equally, the use of dominant-negative Rac mutants
has revealed that Rac mediates many of the PI3K-dependent
pathways. However, it is very obvious that Rac does not
mediate all PI3K pathways, a classic example of a PI3K-de-
pendent but Rac-independent response being insulin-stimu-
lated glucose transport [10]. Inversely, it is also clear that
Rac cannot only be activated by PI3K. Some Rac-dependent
cellular responses, such as membrane ru¥ing in bombesin-
stimulated Swiss 3T3 cells [11], or activation of transcription
factor AP1 in T cell receptor (TCR)-stimulated Jurkat T cells
[12], are insensitive to PI3K inhibitors. In fact, multiple path-
ways of Rac activation seem to co-exist within any cell type.
For example, in neutrophils, PMA can stimulate Rac2 activa-
tion in a wortmannin-insensitive manner whereas N-formyl-
methionyl-leucyl-phenylalanine (fMLP)-stimulated Rac2 acti-
vation is wortmannin-sensitive, suggesting the co-existence of
PKC- and PI3K-dependent activators of Rac2 in these cells
[13]. The PI3K dependence of fMLP-stimulated Rac activa-
tion in neutrophils has been controversial. In contrast to the
study be Akasaki et al. [13], two other equally convincing
studies found it to be PI3K-independent [14,15], a main ob-
vious di¡erence being the times of stimulation studied. This
apparent contradiction might now be explained by the discov-
ery of P-Rex1, which we now know can receive both PI3K-
dependent and PI3K-independent regulatory inputs ([16], and
see below). However, the relative importance of PI3K-depen-
dent versus PI3K-independent pathways of Rac activation for
a given downstream response is still unclear in most circum-
stances.
3. PI3K-dependent Rac-GEFs
More than a dozen Rac-GEFs have been identi¢ed so far,
some of them speci¢c for the Rac family, some more promis-
cuous [3]. Among them, members of the Vav, Sos, Tiam, PIX,
SWAP-70 and P-Rex families have been suggested to be regu-
lated by PI3K in vivo. In vitro, PtdIns(3,4,5)P3 directly and
strongly activates the Rac-GEF activities of P-Rex1 and
SWAP-70 [16,17], weakly (about two-fold) those of Vav1,
Sos1 and possibly Tiam1 (although the latter is controversial)
[18^21], but probably not that of KPIX [22] (Fig. 2). The
abilities of the other known Rac-GEF families (namely
Trio, Ras-GRF, Asef, Gef-H1 and Fir) to be activated by
PI3K in vivo and/or to bind PtdIns(3,4,5)P3 in vitro have
not yet been studied.
Like all GEFs for Rho family GTPases, Rac-GEFs have
tandem Dbl homology (DH)/PH domains, the DH domain
being the catalytic guanine-nucleotide exchange domain. The
PH domains in these DH/PH tandems do not conform to the
consensus sequence for speci¢c binding of PI3K products:
they all substitute some of the conserved basic residues with
others, including acidic amino acids [23]. Functionally, the PH
domain in the DH/PH tandem di¡ers from those that specif-
ically bind PI3K products, such as in PKB and Dapp1, in one
important aspect: wherever investigated so far, phosphoinosi-
tide binding to the PH domain in the DH/PH tandem is not
su⁄cient to target the Rac-GEF to the membrane. So, while
membrane localisation of the GEF is generally accepted to be
a prerequisite for Rac activation, this is achieved through
domains other than the PH domain in the DH/PH tandem,
although that might cooperate with other membrane targeting
mechanisms. In the cases of Sos1 and Vav1, PtdIns(3,4,5)P3
binding to the PH domain is believed to relieve an intramo-
lecular inhibition that allows activation [18,19,24]. However,
the precise roles of the di¡erent GEF PH domains clearly
need to be studied further.
3.1. Vav
The Vav family has three members, Vav1, 2 and 3. The
regulation of Vav1 is the most intensely studied of all Rac-
GEFs. Upon stimulation of a variety of membrane receptors,
Vav1 is phosphorylated by intracellular protein-tyrosine ki-
nases of the Src or Syk families [25], and this tyrosine phos-
phorylation is su⁄cient to activate Vav1 Rac-GEF activity in
vitro and in vivo [26]. The nuclear magnetic resonance (NMR)
Fig. 1. Mechanisms of Rac activation. Signals for the activation of
Rac ( = exchange of GDP for GTP) can be transmitted in PI3K-de-
pendent and in PI3K-independent ways via the activation of GEFs.
Several families of Rac-GEFs can be activated directly by the lipid
product of PI3K activity, PtdIns(3,4,5)P3.
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structure of a fragment of Vav1 revealed that this phosphor-
ylation relieves an autoinhibitory interaction between Y174
and the DH domain [27]. PI3K is thought to modulate the
activation of Vav1 by in£uencing its degree of tyrosine phos-
phorylation. A widely accepted model is that PtdIns(3,4,5)P3
binding to Vav1 relieves an intramolecular interaction be-
tween PH and DH domains, thus facilitating tyrosine phos-
phorylation on Y174 and so further opening of the DH/PH
domains, binding of Rac-GDP and catalysis [18,19]. How
important though is the input of PI3K to Vav1 regulation
in vivo? Experiments with PI3K inhibitors suggest that this
depends entirely on the signalling pathway studied, and pos-
sibly on the type of protein-tyrosine kinase that phosphory-
lates Vav1 in a given signalling complex [19,25]. For example,
in BCR-stimulated B cells that signal via Syk, Vav1 activity is
not a¡ected by PI3K, whereas in T cells Fyn-mediated tyro-
sine phosphorylation and PI3K cooperate to activate Vav1
[25]. Regulation of another Vav family member, Vav2, seems
to di¡er slightly. Its activation downstream of EGF receptor
stimulation requires PI3K activity whereas tyrosine phosphor-
ylation does not a¡ect its catalytic activity but is instead be-
lieved to regulate protein^protein interactions [28]. As for
Vav1 though, PI3K-dependent activation of Vav2 does not
induce its translocation to the membrane [29]. The regulation
of the third family member, Vav3, by PI3K has not been
studied yet. However, two recent studies have suggested
that, in reverse, Vav3-dependent activation of Rac results in
downstream activation of PI3K (see also below) [30,31].
3.2. Sos
Sos is a dual-speci¢city GEF, with one Ras-speci¢c catalytic
domain and another for Rac. In vitro, PtdIns(3,4,5)P3 has
been shown to bind to the PH domain of the DH/PH frag-
ment [19] and to weakly activate Rac-GEF activity in Sos1
immunoprecipitates from COS cells [20]. In vivo, activation of
the DH/PH fragment requires PI3K activity [24]. Hence, as
with Vav1, PtdIns(3,4,5)P3 binding to Sos1 is believed to ac-
tivate its Rac-GEF activity by relieving an intramolecular in-
hibition [19,24]. In vivo, Sos1 functions as a Rac-GEF down-
stream of receptor-tyrosine kinases in a complex with the
proteins Eps8 and Abi1 [32,33]. Localisation of Sos1 to actin
structures is mediated by Eps8 [33], while its Rac-GEF activ-
Fig. 2. Domain structures of Rac-GEFs that are activated by PI3K and/or bind PI3K products. The domain predictions were made using
SMART (http://smart.embl-heidelberg.de). The inositol polyphosphate 4-phosphatase homology of P-Rex1 and the DH domain of SWAP-70
were added manually, as their homologies are too weak for SMART. The Rac-GEF activities of P-Rex1 and SWAP-70 are directly and
strongly activated by PtdIns(3,4,5)P3, whereas Vav1, Sos1 and (perhaps) Tiam1 are activated weakly. KPIX and Dock180 are probably not acti-
vated directly by PtdIns(3,4,5)P3.
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ity appears to depend on the interaction of the p85 regulatory
subunit of type 1A PI3K with Abi1 [20]. The upstream signal
for recruitment of p85 to this complex is unclear, it appears
to be constitutively associated. Addition of short-chain
PtdIns(3,4,5)P3 to the immunoprecipitated complex circum-
vents the need for p85 binding to allow Sos1 to exhibit
Rac-GEF activity [20], suggesting that the role of p85 binding
is to recruit the catalytic PI3K subunit. However, association
of actual PI3K activity with the complex and the e¡ect of
PtdIns(3,4,5)P3 in a proper liposome environment remain to
be established.
3.3. Tiam
Tiam1 is a Rac-GEF with two PH domains, the C-terminal
one being the tandem DH/PH one. Tiam1 membrane associ-
ation is mainly mediated by the N-terminal PH domain and
an adjacent protein/protein interaction domain [34]. Although
the N-terminal PH domain binds PtdIns(3,4,5)P3 on ‘fat-
blots’ [21], Tiam translocation to the membrane does not re-
quire PI3K activity [21,35]. The role of PI3K in the activation
of Tiam is controversial. The Der lab showed clearly that
Tiam1 can be activated by Ras directly and independently
of PI3K [36]. Another mechanism of Tiam1 activation is
through phosphorylation by Ca2þ/calmodulin-dependent ki-
nase II [37]. Confusingly, di¡erent studies show either that
PI3K is required for Tiam1 Rac-GEF activity in vivo [38],
and that PtdIns(3,4,5)P3 can activate it in vitro (two-fold)
[21], or that its activation is PI3K-independent [36]. Unusually
for PH domains, the C-terminal Tiam PH domain (in the DH/
PH tandem) binds PtdIns3P [39]. PtdIns3P is a PI3K product
that can theoretically be made by all types of PI3Ks and is
enriched in endosomal and phagosomal membranes [4,40].
Point mutations in the C-terminal PH domain that abolish
PtdIns3P binding also abolish the Rac-GEF activity of full-
length Tiam1, without a¡ecting its membrane association
[41].
3.4. KPIX
KPIX is a GEF that regulates Rac and CDC42 activation
downstream of receptor-tyrosine kinases and integrins. Co-
expression of membrane-targeted type 1A PI3K with KPIX
stimulates its Rac-GEF activity in vivo [22]. Also, lipid
vesicles made from dipalmitoyl-PtdIns(3,4,5)P3, when added
to cell culture medium, stimulate Rac-GTP loading in KPIX-
transfected but not control cells. Although this method is
highly unorthodox, it seems to support the results obtained
by overexpression of PI3K [22]. The e¡ects of PtdIns(3,4,5)P3
on KPIX Rac-GEF activity in vitro have not yet been estab-
lished, but activation of its CDC42-GEF activity by
PtdIns(3,4,5)P3 is poor [22], suggesting that the e¡ects ob-
served in vivo may not be direct.
3.5. P-Rex1
P-Rex1 is a Rac-speci¢c GEF that is mainly expressed in
neutrophils [16]. It is so far the only Rac-GEF puri¢ed from
tissue to homogeneity on the basis of its PtdIns(3,4,5)P3-de-
pendent Rac-GEF activity and represents the major such ac-
tivity in neutrophils. It is substantially, directly and synergis-
tically activated by PtdIns(3,4,5)P3 and GLQ subunits both in
vitro and in vivo. Its activation in vitro by PtdIns(3,4,5)P3 is
about 20-fold, and it is currently the only Rac-GEF known to
be activated directly by GLQs. P-Rex1 is thus a good candidate
to explain Rac activation in a type 1B PI3K-regulated signal-
ling pathway, downstream of G protein-coupled receptors
[16]. Mutational analysis is now needed to de¢ne the binding
sites of PtdIns(3,4,5)P3 and GLQs on P-Rex1 and their relative
importance for P-Rex1 signalling in vivo.
3.6. SWAP-70
SWAP-70 was originally identi¢ed as a protein regulating
B cell activation and immunoglobulin class switching. It was
not at ¢rst recognised to be a GEF, because its PH domain is
not preceded by a DH domain. SWAP-70 was puri¢ed from a
crude bovine brain lysate by ¢shing with PtdIns(3,4,5)P3
beads [17]. Only then, careful sequence analysis revealed a
weak homology of its C-terminus with DH domains (on the
‘wrong’ side of the PH domain), and indeed SWAP-70 turned
out to be a PtdIns(3,4,5)P3-dependent Rac-speci¢c GEF in
vitro (the level of its activation by PtdIns(3,4,5)P3 seems com-
parable to that of P-Rex1). SWAP-70 is involved in signalling
downstream of type 1A PI3K-linked membrane receptors in
vivo [17].
3.7. Dock180
Dock180 is not a classic GEF, but it is an upstream regu-
lator of Rac that acts in a complex with ELMO [42]. Nucle-
otide-free Rac can bind directly to a region in Dock180 de-
noted Docker. In the presence of GTP, this interaction leads
to increased Rac-GTP loading, which is why Dock180 has
been named a Rac-GEF. However, Dock180 neither has a
DH nor PH domain and is unable to bind GDP-bound
Rac. Thus, in order for the Dock180/ELMO complex to con-
tribute to Rac activation, there remains a requirement for
another enzyme to remove the GDP from Rac. Interestingly,
there is a possibility that PI3K might directly regulate
Dock180 in some way, as PtdIns(3,4,5)P3 can bind to a basic
region at the C-terminus of Dock180 (that is not a PH do-
main), albeit without any e¡ect on Rac-GTP loading [43].
PI3K is clearly an important upstream regulator of Rac-
GEFs. More in vitro studies are needed, especially with point-
mutated full-length GEFs in carefully controlled liposome en-
vironments, to better understand the importance of phosphoi-
nositide binding to the PH domain in the DH/PH tandem.
Also, more in vivo studies are needed to see how important
the input of PI3K is for the activation of Rac-GEFs relative
to other regulatory mechanisms in a given signalling pathway.
4. Rac upstream of PI3K
Evidence has been around for many years that Rac can act
upstream of PI3K [44,30,31]. The mechanism for this is un-
clear. In vitro, GTP-bound but not GDP-bound Rac can bind
directly to the p85 regulatory subunit of class 1A PI3K [45^
47]. The interaction is via the BCR homology domain in p85
and the e¡ector domain of active Rac [45]. One lab has found
that this interaction stimulates PI3K in vitro activity [45],
whereas another lab found no e¡ect [46]. However, there is
no evidence that this is a mechanism by which Rac-mediated
PI3K activation can occur in vivo. Recently, the Bourne lab
has provided convincing evidence for a positive feedback
loop, whereby Rac, once activated by PI3K, can in turn fur-
ther activate PI3K [48,49]. This positive feedback loop may
play a crucial role in establishing cell polarity in neutrophils,
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which is a prerequisite for chemotaxis. However, the molec-
ular mechanisms of this feedback loop are still unde¢ned.
5. Future work
The links between PI3K and Rac signalling are clearly es-
sential for the regulation of cellular responses ranging from
transcription, translation, protein synthesis, cell survival and
cell cycle entry to the structure of the actin cytoskeleton.
Future studies must show the relative importance of PI3K
for Rac activation compared to other regulatory inputs. De-
tailed comparisons between di¡erent Rac signalling pathways
within a cell type and between di¡erent cell types are needed
to address this. It will also be interesting to see whether PI3K
can regulate Rac by other means than via GEFs, e.g. by
controlling the inhibition of GAPs or the dissociation of
GDIs, both possibilities that have been a little neglected so
far. And lastly, the regulatory mechanisms and functional
importance of Rac-dependent activation of PI3K clearly
need to be studied further.
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